

E1

28. (Twice amended) A soluble polypeptide comprising in sequence three short consensus repeats (SCR) of long homologous repeat A (LHR-A) (SEQ ID NO: 59) selected from the group consisting of SCR 1, 2, 3, and 4, and including at least SCR3, wherein at least one of the SCR native amino acids is substituted, wherein the substitute amino acid is selected from the group consisting of Val at position 4, Asp at position 19, Ser at position 53, Lys at position 57, Ala at position 74, Asp at position 79, Arg at position 84, Pro at position 91, Asn at position 109, Lys at position 116, Val at position 119, Ala at position 132, Thr at position 137, Ile at position 139, Ser at position 140, Tyr at position 143, His at position 153, Leu at position 156, Arg at position 159, Lys at position 161, Lys at position 177, Gly at position 230, Ser at position 235, and His at position 236, wherein each position is based upon the mature LHR-A sequence.

29. (Twice amended) The polypeptide according to claim 28, wherein the polypeptide comprises one selected from the group consisting of SCR 1, 2, 3 and 4 of LHR-A or SCR 1, 2 and 3 of LHR-A.

E2

42. (Twice amended) A soluble derivative of a soluble polypeptide, wherein said soluble derivative comprises in sequence three short consensus repeats (SCR) of long homologous repeat A (LHR-A) (SEQ ID NO: 59) selected

E2 from the group consisting of SCR 1, 2, 3, and 4, and including at least SCR3, wherein at least one of the SCR native amino acids is substituted, wherein the substitute amino acid is selected from the group consisting of Val at position 4, Asp at position 19, Ser at position 53, Lys at position 57, Ala at position 74, Asp at position 79, Arg at position 84, Pro at position 91, Asn at position 109, Lys at position 116, Val at position 119, Ala at position 132, Thr at position 137, Ile at position 139, Ser at position 140, Tyr at position 143, His at position 153, Leu at position 156, Arg at position 159, Lys at position 161, Lys at position 177, Gly at position 230, Ser at position 235, His at position 236, wherein each position is based upon the mature LHR-A sequence, and

wherein said soluble derivative comprises at least two heterologous membrane binding elements with low membrane affinity covalently associated with the polypeptide, wherein the elements are capable of interacting independently and with thermodynamic additivity with components of cellular membranes exposed to extracellular fluids, and

wherein the membrane binding elements have an affinity with a dissociation constant of between at least about 1 μ M and 1mM.

E3 49. (Twice amended) A process for preparing a soluble derivative of a soluble polypeptide, wherein said soluble derivative comprises in sequence three short consensus repeats (SCR) of long homologous repeat A (LHR-A) (SEQ ID

NO: 59) selected from the group consisting of SCR 1, 2, 3, and 4, and including at least SCR3, wherein at least one of the SCR native amino acids is substituted, wherein the substitute amino acid is selected from the group consisting of Val at position 4, Asp at position 19, Ser at position 53, Lys at position 57, Ala at position 74, Asp at position 79, Arg at position 84, Pro at position 91, Asn at position 109, Lys at position 116, Val at position 119, Ala at position 132, Thr at position 137, Ile at position 139, Ser at position 140, Tyr at position 143, His at position 153, Leu at position 156, Arg at position 159, Lys at position 161, Lys at position 177, Gly at position 230, Ser at position 235, His at position 236, wherein each position is based upon the mature LHR-A sequence, comprising

E3
expressing DNA encoding the polypeptide portion of said derivative in a recombinant host cell and recovering the product and thereafter post translationally modifying the polypeptide to bind membrane binding elements to the polypeptide.

50. (Twice amended) A pharmaceutical composition comprising (A) a therapeutically effective amount of a soluble polypeptide comprising in sequence three short consensus repeats (SCR) of long homologous repeat A (LHR-A) (SEQ ID NO: 59) selected from the group consisting of SCR 1, 2, 3, and 4, and including at least SCR3, wherein at least one of the SCR native amino acids is substituted, wherein the substitute amino acid is selected from the group consisting of Val at position 4, Asp at position 19, Ser at position 53, Lys at

E3
position 57, Ala at position 74, Asp at position 79, Arg at position 84, Pro at position 91, Asn at position 109, Lys at position 116, Val at position 119, Ala at position 132, Thr at position 137, Ile at position 139, Ser at position 140, Tyr at position 143, His at position 153, Leu at position 156, Arg at position 159, Lys at position 161, Lys at position 177, Gly at position 230, Ser at position 235, His at position 236, wherein each position is based upon the mature LHR-A sequence,

Concluded and (B) a pharmaceutically acceptable carrier or excipient.
